AbbVie Valuation
| ABBV34 Stock | BRL 51.85 0.06 0.12% |
At this time, the firm appears to be fairly valued. AbbVie Inc shows a prevailing Real Value of R$50.27 per share. The current price of the firm is R$51.85. Our model approximates the value of AbbVie Inc from analyzing the firm fundamentals such as return on equity of 0.75, and Profit Margin of 0.20 % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that AbbVie's price fluctuation is very steady at this time. Calculation of the real value of AbbVie Inc is based on 3 months time horizon. Increasing AbbVie's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for AbbVie Inc is useful when determining the fair value of the AbbVie stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of AbbVie. Since AbbVie is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AbbVie Stock. However, AbbVie's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 51.85 | Real 50.27 | Hype 51.85 | Naive 52.18 |
The real value of AbbVie Stock, also known as its intrinsic value, is the underlying worth of AbbVie Inc Company, which is reflected in its stock price. It is based on AbbVie's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of AbbVie's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AbbVie's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AbbVie Inc helps investors to forecast how AbbVie stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AbbVie more accurately as focusing exclusively on AbbVie's fundamentals will not take into account other important factors: AbbVie Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining AbbVie's current stock value. Our valuation model uses many indicators to compare AbbVie value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AbbVie competition to find correlations between indicators driving AbbVie's intrinsic value. More Info.AbbVie Inc is number one stock in price to earning category among related companies. It is number one stock in price to book category among related companies fabricating about 0.20 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for AbbVie Inc is roughly 5.09 . Comparative valuation analysis is a catch-all model that can be used if you cannot value AbbVie by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AbbVie's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AbbVie's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates AbbVie's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in AbbVie and how it compares across the competition.
About AbbVie Valuation
The stock valuation mechanism determines the current worth of AbbVie Inc on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of AbbVie Inc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AbbVie Inc based exclusively on its fundamental and basic technical indicators. By analyzing AbbVie's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of AbbVie's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of AbbVie. We calculate exposure to AbbVie's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to AbbVie's related companies.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. ABBVIE DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 30000 people.
8 Steps to conduct AbbVie's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates AbbVie's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct AbbVie's valuation analysis, follow these 8 steps:- Gather financial information: Obtain AbbVie's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine AbbVie's revenue streams: Identify AbbVie's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research AbbVie's industry and market trends, including the size of the market, growth rate, and competition.
- Establish AbbVie's growth potential: Evaluate AbbVie's management, business model, and growth potential.
- Determine AbbVie's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate AbbVie's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |